0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ALK-1

ALK-1

Brief Information

Name:Activin receptor-like kinase 1
Target Synonym:ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT,EC:2.7.11.30,ACVRLK1,Activin A R
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AL1-H5227 Human Human ALK-1 / ACVRL1 Protein, His Tag
AL1-H5227-structure
AL1-H5227-sds

Synonym Name

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

Background

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dalantercept ACE-041 Phase 2 Clinical Acceleron Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Multiple Myeloma; Carcinoma, Hepatocellular Details
Ascrinvacumab PF-03446962; PF-3446962; GT-90001; PF-3-446-962; GT-90001C; GT90001C; ALK-1 Phase 2 Clinical Pfizer Inc Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration Details

This web search service is supported by Google Inc.

totop